CR20250272A - Degradación dirigida de vav1 - Google Patents

Degradación dirigida de vav1

Info

Publication number
CR20250272A
CR20250272A CR20250272A CR20250272A CR20250272A CR 20250272 A CR20250272 A CR 20250272A CR 20250272 A CR20250272 A CR 20250272A CR 20250272 A CR20250272 A CR 20250272A CR 20250272 A CR20250272 A CR 20250272A
Authority
CR
Costa Rica
Prior art keywords
structural elements
vav1
structural
supported
bearing surfaces
Prior art date
Application number
CR20250272A
Other languages
English (en)
Inventor
Andreas Ritzen
Lorenzo Delarue Bizzini
Vladimiras Oleinikovas
Xavier Lucas Cabré
Laura Ann Mcallister
Elisa Liardo
Mathieu Lesieur
Bernhard Fasching
Original Assignee
Monte Rosa Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monte Rosa Therapeutics Ag filed Critical Monte Rosa Therapeutics Ag
Publication of CR20250272A publication Critical patent/CR20250272A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Rod-Shaped Construction Members (AREA)

Abstract

Un sistema estructural de madera técnica que incluye múltiples elementos estructurales verticales (10) que incluyen primeras superficies (11) de asiento comprendidas entre puntales verticales paralelos (12) fabricados de segmentos alineados sucesivos (13) de puntal vertical conectados entre sí, múltiples elementos estructurales horizontales (20, 120), soportados sobre dichas primeras superficies (11) de asiento, incluyendo cada uno un tablero horizontal superior (21) y un tablero horizontal inferior (22) con al menos un segundo separador (23) colocado entre los mismos, y, opcionalmente, miembros (30) de losa soportados sobre dichos elementos estructurales horizontales (20, 120) que definen al menos una planta estructural
CR20250272A 2023-01-09 2024-01-08 Degradación dirigida de vav1 CR20250272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363437951P 2023-01-09 2023-01-09
PCT/US2024/010733 WO2024151547A1 (en) 2023-01-09 2024-01-08 Targeted degradation of vav1

Publications (1)

Publication Number Publication Date
CR20250272A true CR20250272A (es) 2025-10-30

Family

ID=89901081

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250272A CR20250272A (es) 2023-01-09 2024-01-08 Degradación dirigida de vav1

Country Status (14)

Country Link
US (2) US12257247B2 (es)
EP (1) EP4648853A1 (es)
JP (1) JP2026503019A (es)
KR (1) KR20250135228A (es)
CN (1) CN121311479A (es)
AU (1) AU2024207015A1 (es)
CL (1) CL2025001983A1 (es)
CO (1) CO2025009115A2 (es)
CR (1) CR20250272A (es)
DO (1) DOP2025000159A (es)
IL (1) IL321686A (es)
JO (1) JOP20250160A1 (es)
MX (1) MX2025007948A (es)
WO (1) WO2024151547A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026013578A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Combinations comprising vav1-targeting degraders
WO2026013581A1 (en) 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Dosage forms comprising a vav1 degrader
WO2026013576A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Dihydrouracil derivatives useful for the targeted degradation of vav1
WO2026013577A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1
WO2026026773A1 (zh) * 2024-07-29 2026-02-05 杭州胶联生物医药科技有限公司 作为vav1蛋白靶点降解剂的新型取代杂环类化合物
WO2026035999A1 (en) 2024-08-09 2026-02-12 Triana Biomedicines, Inc. Anaplastic lymphoma kinase (alk) degraders and uses thereof
CN121591644A (zh) * 2024-08-22 2026-03-03 武汉人福创新药物研发中心有限公司 作为vav1降解剂的化合物及其用途
CN121591699A (zh) * 2024-08-22 2026-03-03 武汉人福创新药物研发中心有限公司 作为vav1降解剂的苯并杂环类化合物及其用途
WO2026045349A1 (en) * 2024-09-02 2026-03-05 Innocare Pharma Inc. Heterocyclic vav1 degraders
WO2026051943A1 (zh) * 2024-09-04 2026-03-12 上海齐鲁制药研究中心有限公司 Vav1靶向降解剂
WO2026067535A1 (zh) * 2024-09-25 2026-04-02 湖北生物医药产业技术研究院有限公司 Vav1降解剂
WO2026067646A1 (zh) * 2024-09-27 2026-04-02 上海美悦生物科技发展有限公司 联苯类化合物、及其药物组合物和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
BR112021015131A2 (pt) 2019-01-31 2021-09-28 Betta Pharmaceuticals Co., Ltd Imunomoduladores, composições e métodos dos mesmos
WO2020228649A1 (zh) 2019-05-10 2020-11-19 上海海雁医药科技有限公司 取代的苯基丙烯基吡啶类衍生物，其制法与医药上的用途
WO2021011631A1 (en) 2019-07-15 2021-01-21 Kymera Therapeutics, Inc. Fused-glutarimide crbn ligands and uses thereof
EP4031243A1 (en) 2019-09-16 2022-07-27 Novartis AG Glue degraders and methods of use thereof
WO2021180103A1 (en) 2020-03-11 2021-09-16 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CA3172720A1 (en) 2020-03-31 2021-10-07 Nathan FISHKIN Conjugates
WO2022012622A1 (en) 2020-07-16 2022-01-20 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
TW202221000A (zh) 2020-09-30 2022-06-01 英屬開曼群島商百濟神州有限公司 用於降解ｅｇｆｒ之雙功能化合物及相關使用方法
BR112023023065A2 (pt) 2021-05-05 2024-01-30 Biogen Ma Inc Compostos para direcionar a degradação da tirosina quinase de bruton
CN115232125B (zh) 2021-05-14 2024-06-18 杭州和正医药有限公司 多取代苯类免疫调节化合物、组合物及其应用
EP4341254A4 (en) 2021-05-20 2025-04-09 Dana-Farber Cancer Institute, Inc. INHIBITORS AND DEGRADERS OF THE PIP4K PROTEIN
CN115536657A (zh) 2021-06-29 2022-12-30 上海翰森生物医药科技有限公司 一种联苯类衍生物抑制剂的盐、其晶型及其制备方法
TW202330037A (zh) 2021-09-08 2023-08-01 南韓商歐倫醫療公司 用於抗體藥物綴合物之連接子
WO2024018403A1 (en) 2022-07-21 2024-01-25 Arbutus Biopharma Corporation Substituted imidazoamide compounds, and methods using same

Also Published As

Publication number Publication date
CN121311479A (zh) 2026-01-09
US20240285604A1 (en) 2024-08-29
JOP20250160A1 (ar) 2025-07-06
CO2025009115A2 (es) 2025-09-29
EP4648853A1 (en) 2025-11-19
WO2024151547A1 (en) 2024-07-18
IL321686A (en) 2025-08-01
AU2024207015A1 (en) 2025-07-10
CL2025001983A1 (es) 2026-01-02
US12257247B2 (en) 2025-03-25
US20250205219A1 (en) 2025-06-26
MX2025007948A (es) 2025-08-01
KR20250135228A (ko) 2025-09-12
DOP2025000159A (es) 2025-11-30
JP2026503019A (ja) 2026-01-27

Similar Documents

Publication Publication Date Title
CL2024000061A1 (es) Sistema estructural de madera técnica
Durrani et al. Seismic retrofit of flat-slab buildings with masonry infills
GB2594559A8 (en) A grid framework structure
EA201491066A1 (ru) Класс опор для защиты конструкций от землетрясения и других аналогичных опасных факторов
CL2019003797A1 (es) Método parmontaje de un aerogenerador y generador montado según dicho método
CN207525922U (zh) 一种具有摩擦耗能板与肘节耗能节点的复合减振装置
CN210032179U (zh) 一种用于建筑柱顶或柱底的减震消能装置
CN205348921U (zh) 具有抗提离功能的摩擦滑移摆隔震支座
CL2011002779A1 (es) Sistema de andamio con varios elementos de andamio, donde un elemento de andamio comprende dos soportes, al menos dos elementos de refuerzo, un elemento de conexion transversal, donde al menos dos elementos de andamio con elementos de conexion transversal orientados de forma diferente se disponen uno encima del otro; uso.
WO2022111216A1 (zh) 一种低层、多层建筑非结构试验平台及试验方法
CN109024959A (zh) 一种抗震房建结构
JP2016169703A (ja) 免震縦軸風車
CN216429192U (zh) 一种抗风防震结构的钢结构房屋
JP3464094B2 (ja) ユニット建物
CN212779841U (zh) 一种新型摇摆隔震桥墩基础试验台
Monti et al. Effects of multi-support excitation on isolated bridges
CN207891657U (zh) 多刚度轨道隔震装置
CN104912202A (zh) 隔震支座
CN204826281U (zh) 一种建筑防震系统
CL2019001994A1 (es) Sistema de elevación para módulos fotovoltaicos
CN205000239U (zh) 一种桥梁抗震支座
CN106400977A (zh) 一种木质滑移隔震支座
RU2012140221A (ru) Пневмокаркасное сооружение
CL2018003206A1 (es) Panel de placas compuestas para la construcción de losas de entre pisos aligeradas unidireccionales.
Modi et al. Parametric study of various tube in tube structures